INmune Bio Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

INmune Bio wird ein Gewinn- und Umsatzwachstum von 53.4% bzw. 72.4% pro Jahr prognostiziert, während der Gewinn pro Aktie um 47.4% pro Jahr wachsen soll.

Wichtige Informationen

53.4%

Wachstumsrate der Gewinne

47.4%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.4%
Wachstumsrate der Einnahmen	72.4%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	06 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

INmune Bio: Speculative Biotech With 2 Solid Potential Approaches To Treating AD And Solid Tumors

Apr 05

Is INmune Bio (NASDAQ:INMB) A Risky Investment?

Mar 25

Is INmune Bio (NASDAQ:INMB) Using Too Much Debt?

Dec 02

INmune Bio A No-Brainer Investment

Oct 13

INmune Bio: High-Risk High-Reward Alzheimer's Play

Aug 18

Our Bullish Take On INmune Bio's Drug Pipeline

Aug 12

INmune Bio: Underfollowed AD Player With Very Bullish August Momentum

Jul 13

Companies Like INmune Bio (NASDAQ:INMB) Are In A Position To Invest In Growth

Jun 25

INmune enters $15M credit facility to fund purchase of Xencor option

Jun 14

INmune Bio (NASDAQ:INMB) Is In A Strong Position To Grow Its Business

Mar 01

What Kind Of Investors Own Most Of INmune Bio, Inc. (NASDAQ:INMB)?

Jan 05

Here's Why We're Not Too Worried About INmune Bio's (NASDAQ:INMB) Cash Burn Situation

Dec 01

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:INMB - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	0	-49	N/A	N/A	2
12/31/2025	0	-48	N/A	N/A	2
12/31/2024	0	-49	N/A	N/A	3
3/31/2024	0	-34	-18	-18	N/A
12/31/2023	0	-30	-12	-12	N/A
9/30/2023	0	-27	-14	-14	N/A
6/30/2023	0	-27	-13	-13	N/A
3/31/2023	0	-27	-15	-15	N/A
12/31/2022	0	-27	-23	-23	N/A
9/30/2022	0	-31	-27	-27	N/A
6/30/2022	0	-33	-31	-31	N/A
3/31/2022	0	-33	-32	-32	N/A
12/31/2021	0	-30	-29	-29	N/A
9/30/2021	0	-24	-21	-21	N/A
6/30/2021	0	-19	-17	-17	N/A
3/31/2021	0	-15	-13	-13	N/A
12/31/2020	0	-12	-9	-9	N/A
9/30/2020	N/A	-11	-7	-7	N/A
6/30/2020	N/A	-10	-5	-5	N/A
3/31/2020	N/A	-8	-5	-5	N/A
12/31/2019	N/A	-8	-5	-5	N/A
9/30/2019	N/A	-7	-5	-5	N/A
6/30/2019	N/A	-6	-4	-4	N/A
3/31/2019	N/A	-11	-3	-3	N/A
12/31/2018	N/A	-12	-2	-2	N/A
9/30/2018	N/A	-11	-2	-2	N/A
6/30/2018	N/A	-10	-2	-2	N/A
3/31/2018	N/A	-4	-1	-1	N/A
12/31/2017	N/A	-1	N/A	-1	N/A
9/30/2017	N/A	-1	N/A	-1	N/A
12/31/2016	N/A	0	N/A	0	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: INMB wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: INMB wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: INMB wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: INMBDie Einnahmen des Unternehmens (72.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: INMBDie Einnahmen des Unternehmens (72.4% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von INMB in 3 Jahren voraussichtlich hoch sein wird

INmune Bio Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 24%

Consensus revenue estimates decrease by 35%, EPS upgraded

Consensus revenue estimates increase by 30%, EPS downgraded

Consensus revenue estimates increase by 51%

Price target decreased to US$14.33

Consensus revenue estimates increase by 24%

Recent updates

INmune Bio, Inc., Annual General Meeting, Jul 19, 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings released: US$1.67 loss per share (vs US$1.52 loss in FY 2022)

Consensus EPS estimates fall by 24%

INmune Bio, Inc. to Report Q1, 2024 Results on May 09, 2024

INmune Bio, Inc. Provides Update on Two Patients from the Phase 1b Alzheimer's Disease Trial

INmune Bio, Inc. has filed a Follow-on Equity Offering in the amount of $9.70224 million.

Independent Director recently bought US$246k worth of stock

Inmune Bio Inc. Announces 24-Month Stability Validation of Xpro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay

INmune Bio, Inc. has filed a Follow-on Equity Offering.

Consensus revenue estimates decrease by 35%, EPS upgraded

New major risk - Revenue and earnings growth

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

INmune Bio, Inc. to Report Q4, 2023 Results on Mar 28, 2024

INmune Bio, Inc. Reports Significant EEG Improvement in Alzheimer's Patients Treated with XPro

Inmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’S Disease Program

New minor risk - Share price stability

Is INmune Bio (NASDAQ:INMB) Using Debt Sensibly?

INmune Bio, Inc. Provides Update Regarding Global Alzheimer's Phase Ii Clinical Trial and Clinical Hold Issued by the United States FDA

Inmune Bio Inc. Demonstrates That INB03 Enhances the Uptake of Trastuzumab Deruxtecan in Her2+ Breast Cancer with Muc4 Expression in Poster Presented At San Antonio Breast Cancer Symposium

INmune Bio, Inc. Receives EMA's Authorization in France and Spain for Phase II Clinical Trial of XPro for Early Alzheimer's Disease

INmune Bio, Inc. Receives EMA's Authorization in France and Spain for Phase II Clinical Trial of XPro for Early Alzheimer's Disease

INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer's Disease in Europe

Consensus revenue estimates increase by 30%, EPS downgraded

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Inmune Bio, Inc. Announces Update Regarding Patent Claims Covering Inb16 Cell Line

INmune Bio, Inc. Presents New Biomarker and Feasibility Data from Phase 1b Study Supporting the Use of XPro™ to Treat Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease Conference

INmune Bio, Inc. to Report Q3, 2023 Results on Nov 01, 2023

Inmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer’S Disease

Is INmune Bio (NASDAQ:INMB) Using Debt In A Risky Way?

Consensus revenue estimates increase by 51%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

INmune Bio, Inc. to Report Q2, 2023 Results on Aug 07, 2023

INmune Bio Inc. Announces Novel MRI Biomarker Data Demonstrating Improvement in Gray Matter in Patients with Alzheimer’s Disease

INmune Bio, Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro™ Promotes Remyelination by Affecting Astroglial and Microglial Biology

Is INmune Bio (NASDAQ:INMB) Using Too Much Debt?

INmune Bio, Inc. Announces FDA Clearance of IND Application for INKmune, a Natural Killer Therapy, for a Phase I/II Trial in Metastatic Castration-Resistant Prostate Cancer

First quarter 2023 earnings released: US$0.36 loss per share (vs US$0.39 loss in 1Q 2022)

Full year 2022 earnings: EPS and revenues exceed analyst expectations

INmune Bio, Inc. Announces Pre-Clinical Data to Support Pioneering Approach to Treating Duchenne Muscular Dystrophy

Here's Why INmune Bio (NASDAQ:INMB) Can Manage Its Debt Despite Losing Money

INmune Bio, Inc. Reports Combination Therapy with INB03™ Overcomes Resistance to Trastuzumab-Deruxtecan in MUC4 Expressing HER2+ Breast Cancer

Insufficient new directors

INmune Bio, Inc. Focuses on Novel Clinical Trial Designs to Advance Next Generation of Alzheimer’s Disease Treatments

Price target decreased to US$14.33

Inmune Bio, Inc. Receives Health Canada “No Objection Letter” to Commence Clinical Trial of Xpro1595 in Mild Alzheimer’S Disease

Consensus revenue estimates increase by 24%

Third quarter 2022 earnings released: US$0.43 loss per share (vs US$0.55 loss in 3Q 2021)

INmune Bio, Inc. to Report Q3, 2022 Results on Nov 02, 2022

INmune Bio, Inc. Announces Positive Solid Tumor Efficacy Data in Multiple Cancer Cell Lines for INKmune

Second quarter 2022 earnings released: US$0.38 loss per share (vs US$0.44 loss in 2Q 2021)

Here's Why INmune Bio (NASDAQ:INMB) Can Manage Its Debt Despite Losing Money

CFO, Treasurer & Secretary recently bought US$69k worth of stock

INmune Bio: Possibly The Once In A Lifetime Dip

INmune Bio, Inc. Provides Additional Manufacturing Information to FDA as Part of IND Application for XPro1595™ in Alzheimer’s Disease

Inmune Bio, Inc. Presents Data Demonstrating Xpro™ Promotes Remyelination in Gray Matter At 3rd European Conference on Neuroinflammation

Price target decreased to US$22.33

INmune Bio, Inc., Annual General Meeting, Jun 01, 2022

INmune Bio, Inc. Announces Dosing of First Patient Enrolled in its Phase 2 Trial Using XPro1595 (XPro™) to Treat Neuroinflammation as Cause of Alzheimer’s Disease

INmune Bio, Inc. to Present Preclinical Data on INB03 at the American Association for Cancer Research Annual Meeting 2022

INmune Bio, Inc. Highlights INKmune™ Data Featured in NK Cells in Solid Tumors Workshop at Innate Killer Summit

INmune Bio: Speculative Biotech With 2 Solid Potential Approaches To Treating AD And Solid Tumors

Is INmune Bio (NASDAQ:INMB) A Risky Investment?

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

INmune Bio, Inc. to Report Q4, 2021 Results on Mar 03, 2022

Price target decreased to US$24.33

Is INmune Bio (NASDAQ:INMB) Using Too Much Debt?

Price target increased to US$35.00

INmune Bio A No-Brainer Investment